Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedra warning letters

This article was originally published in The Tan Sheet

Executive Summary

Universal Nutrition, which received FDA warning letter to discontinue ephedra athletic performance claims, says it has submitted response to agency pledging compliance and requesting clarification on some points; firm also has revised language on its Web site, labeling. New Brunswick, N.J.-based firm said it is debating whether or not to exit ephedra market. Other FDA letter recipients including American Body Building, Advanced Pharmaceuticals have issued similar responses to agency, which sent the letters in late February (1"The Tan Sheet" March 3, 2003, p. 8)...

You may also be interested in...



Ephedra Athletic Performance Claims Targeted In FDA Warning Letters

Athletic performance claims for ephedrine alkaloid-containing dietary supplements should be discontinued unless they can be scientifically supported, FDA states in Feb. 28 warning letters to 26 marketers

Ireland Embarks On New Stage Of Drug Verification System

The bedding-in period is ending for Europe’s one-year-old system for preventing the circulation of fake medicines, and the scheme is gearing up for a more fully operational stage. 

DDD Bringing New Life To UK’s Baby-Care Category

DDD Ltd's global marketing director Katy Holder tells HBW Insight how the company is looking to carve out a niche in the UK's baby-care market with naturally derived ingredients and family-friendly product portfolios. 

Topics

UsernamePublicRestriction

Register

PS095279

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel